Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide- carboplatin/cisplatin as first-line tre

• 作 者: Yue-Ya Li Chan Zhou Deng-Xia Y
• 机 构: DepartmentofThoracicOncology
• 出 处: 癌症生物学与医学：英文版
• 发表日期: 2015年2期
• 关键词: 治疗方案 足叶乙甙 紫杉醇 顺铂 卡铂 肺癌 细胞 TEP Small cell lung carcinoma （SCLC） chemotherapy CE
• 基金项目: This study was supported by grants from the Tian）in Municipal Science and Technology Proiect （Grant No. 11JCYBJC 11300）, National Natural Science Foundation of China （Grant No. 81372517）, and National

Objective: To compare the efficacy and adverse effects of paclitaxel-etoposide-carboplatin/cisplatin(TEP/TCE) regimen with those of etoposide-carboplatin/cisplatin(EP/CE) regimen as first-line treatment for combined small-cell lung cancer(CSCLC).Methods: